Refractory Systemic Lupus Erythematosus Clinical Trials

7 recruitingLast updated: June 17, 2026

There are 7 actively recruiting refractory systemic lupus erythematosus clinical trials across 1 country. Studies span Phase 1, Early Phase 1, Phase 2, Not Applicable. Top locations include Beijing, China, Guangzhou, Guangdomg, China, Beijing, Beijing Municipality, China. Updated daily from ClinicalTrials.gov.


Refractory Systemic Lupus Erythematosus Trials at a Glance

7 actively recruiting trials for refractory systemic lupus erythematosus are listed on ClinicalTrialsFinder across 6 cities. The largest study group is Phase 1 with 4 trials, with the heaviest enrollment activity in Beijing, Guangzhou, and Beijing. Lead sponsors running refractory systemic lupus erythematosus studies include Beijing Boren Hospital, Gracell Biotechnologies (Shanghai) Co., Ltd., and Beijing Biotech.

Browse refractory systemic lupus erythematosus trials by phase

Treatments under study

About Refractory Systemic Lupus Erythematosus Clinical Trials

Looking for clinical trials for Refractory Systemic Lupus Erythematosus? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Refractory Systemic Lupus Erythematosus trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Refractory Systemic Lupus Erythematosus clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 1

NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis

Refractory Lupus NephritisRefractory Systemic Lupus Erythematosus
Guangdong Provincial People's Hospital18 enrolled1 locationNCT06676631
Recruiting
Early Phase 1

IASO207 Injection for Active Refractory Systemic Lupus Erythematosus (SLE)

Refractory Systemic Lupus Erythematosus
Peking University People's Hospital18 enrolled1 locationNCT07617740
Recruiting
Phase 1Phase 2

A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus

Refractory Systemic Lupus Erythematosus
Gracell Biotechnologies (Shanghai) Co., Ltd.118 enrolled2 locationsNCT06530849
Recruiting
Phase 1Phase 2

SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus

Lupus NephritisRefractory Systemic Lupus Erythematosus
Beijing Biotech24 enrolled1 locationNCT07523542
Recruiting
Phase 1

Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases

Relapsed/Refractory Systemic Lupus ErythematosusRelapsed/Refractory Systemic SclerosisRelapsed/Refractory Idiopathic Inflammatory Myopathies+3 more
Beijing Boren Hospital12 enrolled1 locationNCT07361094
Recruiting
Early Phase 1

the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases

Recurrent or Refractory Systemic Lupus ErythematosusRecurrent or Refractory IgG4 Related DiseasesRecurrent or Refractory Systemic Sclerosis+2 more
Tongji Hospital45 enrolled1 locationNCT07339540
Recruiting
Not Applicable

IM19 CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus (SLE)

Refractory Systemic Lupus Erythematosus
Peking University Third Hospital6 enrolled1 locationNCT06513429